Microbot Medical (MBOT) Stock Analysis & Winston Score
Microbot Medical is a small medical device company that designs tiny robots meant to work inside the human body. Its main product is the LIBERTY Endovascular Robotic System, a device that helps doctors perform minimally invasive procedures inside blood vessels without needing to manually guide catheters by hand. The company targets hospitals and interventional physicians, primarily in the cardiovascular and neurovascular space. Microbot makes money by selling or licensing its robotic medical devices, though it is still in early development and has not yet generated meaningful revenue. The company is based in the United States and Israel, and with a market cap of roughly $100 million, it is very small compared to established medical robot makers like Intuitive Surgical. The negative gross and operating margins show the company is spending far more than it earns, and the key risk is whether it can secure regulatory approvals, attract hospital customers, and raise enough capital to survive before running out of cash.
Winston Score: 8/100 — Weak
Weak fundamentals across most pillars.
- Quality: Weak (1/30)
- Growth: Weak (1/20)
- Cash Flow: Weak (0/10)
- Stability: Good (5/10)
- Valuation: Data not available (0/10)
- Ownership: Weak (1/15)
Key Facts
Price: $1.75
Market Cap: $80M
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Exchange: NASDAQ
